Is RLMD or VTVT more profitable?

vTv Therapeutics' return on equity of -6.27% beat Relmada Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Relmada Therapeutics N/A -47.52% -43.97% vTv Therapeutics N/A -6.27% -5.06%

Does the media prefer RLMD or VTVT?

In the previous week, Relmada Therapeutics had 5 more articles in the media than vTv Therapeutics. MarketBeat recorded 9 mentions for Relmada Therapeutics and 4 mentions for vTv Therapeutics. Relmada Therapeutics' average media sentiment score of 1.59 beat vTv Therapeutics' score of 1.50 indicating that Relmada Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Relmada Therapeutics 5 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive vTv Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is VTVT or AVIR more profitable?

vTv Therapeutics' return on equity of -6.27% beat Atea Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets vTv Therapeutics N/A -6.27% -5.06% Atea Pharmaceuticals N/A -64.25% -57.12%

Does the media refer more to VTVT or AVIR?

In the previous week, Atea Pharmaceuticals had 1 more articles in the media than vTv Therapeutics. MarketBeat recorded 5 mentions for Atea Pharmaceuticals and 4 mentions for vTv Therapeutics. vTv Therapeutics' average media sentiment score of 1.50 beat Atea Pharmaceuticals' score of 0.94 indicating that vTv Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment vTv Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Atea Pharmaceuticals 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer BIOA or VTVT?

In the previous week, BioAge Labs had 13 more articles in the media than vTv Therapeutics. MarketBeat recorded 17 mentions for BioAge Labs and 4 mentions for vTv Therapeutics. vTv Therapeutics' average media sentiment score of 1.50 beat BioAge Labs' score of 0.55 indicating that vTv Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioAge Labs 3 Very Positive mention(s) 2 Positive mention(s) 9 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive vTv Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend VTVT or CGC?

vTv Therapeutics presently has a consensus price target of $55.83, indicating a potential upside of 74.64%. Given vTv Therapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe vTv Therapeutics is more favorable than Canopy Growth. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score vTv Therapeutics 1 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 2.78 Canopy Growth 1 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.20

Does the media refer more to VTVT or CGC?

In the previous week, Canopy Growth had 2 more articles in the media than vTv Therapeutics. MarketBeat recorded 6 mentions for Canopy Growth and 4 mentions for vTv Therapeutics. vTv Therapeutics' average media sentiment score of 1.50 beat Canopy Growth's score of 0.86 indicating that vTv Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment vTv Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Canopy Growth 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Positive

Does the media prefer FENC or VTVT?

In the previous week, Adherex Technologies had 8 more articles in the media than vTv Therapeutics. MarketBeat recorded 12 mentions for Adherex Technologies and 4 mentions for vTv Therapeutics. vTv Therapeutics' average media sentiment score of 1.50 beat Adherex Technologies' score of -0.22 indicating that vTv Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Adherex Technologies 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral vTv Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

vTv Therapeutics (VTVT) Competitors

$31.97 +0.11 (+0.35%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$31.98 +0.01 (+0.03%)

As of 09/11/2026 07:30 PM Eastern

Compare

VTVT vs. RLMD, AVIR, BIOA, CGC, and FENC

Should you buy vTv Therapeutics stock or one of its competitors? vTv Therapeutics's main competitors and comparable companies include Relmada Therapeutics (RLMD), Atea Pharmaceuticals (AVIR), BioAge Labs (BIOA), Canopy Growth (CGC), and Adherex Technologies (FENC). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does vTv Therapeutics compare to Relmada Therapeutics?

Relmada Therapeutics (NASDAQ:RLMD) and vTv Therapeutics (NASDAQ:VTVT) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their dividends, institutional ownership, profitability, media sentiment, analyst recommendations, earnings, valuation and risk.

45.2% of Relmada Therapeutics shares are owned by institutional investors. Comparatively, 17.5% of vTv Therapeutics shares are owned by institutional investors. 14.5% of Relmada Therapeutics shares are owned by insiders. Comparatively, 6.0% of vTv Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

vTv Therapeutics has higher revenue and earnings than Relmada Therapeutics. vTv Therapeutics is trading at a lower price-to-earnings ratio than Relmada Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Relmada Therapeutics	N/A	N/A	-$57.38M	-$0.90	N/A
vTv Therapeutics	$1.02M	123.49	-$26.97M	-$1.06	N/A

Relmada Therapeutics currently has a consensus price target of $12.00, suggesting a potential upside of 165.49%. vTv Therapeutics has a consensus price target of $55.83, suggesting a potential upside of 74.64%. Given Relmada Therapeutics' higher possible upside, analysts clearly believe Relmada Therapeutics is more favorable than vTv Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Relmada Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75
vTv Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78

vTv Therapeutics' return on equity of -6.27% beat Relmada Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Relmada Therapeutics	N/A	-47.52%	-43.97%
vTv Therapeutics	N/A	-6.27%	-5.06%

Relmada Therapeutics has a beta of 0.45, suggesting that its share price is 55% less volatile than the broader market. Comparatively, vTv Therapeutics has a beta of 0.29, suggesting that its share price is 71% less volatile than the broader market.

In the previous week, Relmada Therapeutics had 5 more articles in the media than vTv Therapeutics. MarketBeat recorded 9 mentions for Relmada Therapeutics and 4 mentions for vTv Therapeutics. Relmada Therapeutics' average media sentiment score of 1.59 beat vTv Therapeutics' score of 1.50 indicating that Relmada Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Relmada Therapeutics	5 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
vTv Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Relmada Therapeutics beats vTv Therapeutics on 8 of the 14 factors compared between the two stocks.

How does vTv Therapeutics compare to Atea Pharmaceuticals?

vTv Therapeutics (NASDAQ:VTVT) and Atea Pharmaceuticals (NASDAQ:AVIR) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their institutional ownership, media sentiment, risk, dividends, profitability, analyst recommendations, earnings and valuation.

17.5% of vTv Therapeutics shares are owned by institutional investors. Comparatively, 86.7% of Atea Pharmaceuticals shares are owned by institutional investors. 6.0% of vTv Therapeutics shares are owned by company insiders. Comparatively, 21.6% of Atea Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

vTv Therapeutics presently has a consensus price target of $55.83, suggesting a potential upside of 74.64%. Atea Pharmaceuticals has a consensus price target of $7.00, suggesting a potential upside of 31.83%. Given vTv Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe vTv Therapeutics is more favorable than Atea Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
vTv Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78
Atea Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.33

In the previous week, Atea Pharmaceuticals had 1 more articles in the media than vTv Therapeutics. MarketBeat recorded 5 mentions for Atea Pharmaceuticals and 4 mentions for vTv Therapeutics. vTv Therapeutics' average media sentiment score of 1.50 beat Atea Pharmaceuticals' score of 0.94 indicating that vTv Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
vTv Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Atea Pharmaceuticals	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

vTv Therapeutics' return on equity of -6.27% beat Atea Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
vTv Therapeutics	N/A	-6.27%	-5.06%
Atea Pharmaceuticals	N/A	-64.25%	-57.12%

vTv Therapeutics has a beta of 0.29, meaning that its share price is 71% less volatile than the broader market. Comparatively, Atea Pharmaceuticals has a beta of 0.28, meaning that its share price is 72% less volatile than the broader market.

vTv Therapeutics has higher revenue and earnings than Atea Pharmaceuticals. vTv Therapeutics is trading at a lower price-to-earnings ratio than Atea Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
vTv Therapeutics	$1.02M	123.49	-$26.97M	-$1.06	N/A
Atea Pharmaceuticals	N/A	N/A	-$158.35M	-$2.08	N/A

Summary

vTv Therapeutics beats Atea Pharmaceuticals on 10 of the 14 factors compared between the two stocks.

How does vTv Therapeutics compare to BioAge Labs?

BioAge Labs (NASDAQ:BIOA) and vTv Therapeutics (NASDAQ:VTVT) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, dividends, risk, earnings, profitability, media sentiment and valuation.

BioAge Labs presently has a consensus target price of $36.57, indicating a potential upside of 330.76%. vTv Therapeutics has a consensus target price of $55.83, indicating a potential upside of 74.64%. Given BioAge Labs' higher possible upside, research analysts clearly believe BioAge Labs is more favorable than vTv Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioAge Labs	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
vTv Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78

17.5% of vTv Therapeutics shares are owned by institutional investors. 17.6% of BioAge Labs shares are owned by company insiders. Comparatively, 6.0% of vTv Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

BioAge Labs has a beta of 0.94, indicating that its share price is 6% less volatile than the broader market. Comparatively, vTv Therapeutics has a beta of 0.29, indicating that its share price is 71% less volatile than the broader market.

vTv Therapeutics has lower revenue, but higher earnings than BioAge Labs. vTv Therapeutics is trading at a lower price-to-earnings ratio than BioAge Labs, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioAge Labs	$8.99M	43.35	-$80.61M	-$2.38	N/A
vTv Therapeutics	$1.02M	123.49	-$26.97M	-$1.06	N/A

In the previous week, BioAge Labs had 13 more articles in the media than vTv Therapeutics. MarketBeat recorded 17 mentions for BioAge Labs and 4 mentions for vTv Therapeutics. vTv Therapeutics' average media sentiment score of 1.50 beat BioAge Labs' score of 0.55 indicating that vTv Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioAge Labs	3 Very Positive mention(s)	2 Positive mention(s)	9 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
vTv Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

vTv Therapeutics has a net margin of 0.00% compared to BioAge Labs' net margin of -912.26%. vTv Therapeutics' return on equity of -6.27% beat BioAge Labs' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioAge Labs	-912.26%	-28.99%	-27.09%
vTv Therapeutics	N/A	-6.27%	-5.06%

Summary

vTv Therapeutics beats BioAge Labs on 10 of the 16 factors compared between the two stocks.

How does vTv Therapeutics compare to Canopy Growth?

vTv Therapeutics (NASDAQ:VTVT) and Canopy Growth (NASDAQ:CGC) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, risk, profitability, institutional ownership, media sentiment, valuation, earnings and analyst recommendations.

vTv Therapeutics has a beta of 0.29, meaning that its share price is 71% less volatile than the broader market. Comparatively, Canopy Growth has a beta of 0.83, meaning that its share price is 17% less volatile than the broader market.

17.5% of vTv Therapeutics shares are owned by institutional investors. Comparatively, 3.3% of Canopy Growth shares are owned by institutional investors. 6.0% of vTv Therapeutics shares are owned by company insiders. Comparatively, 0.4% of Canopy Growth shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Canopy Growth had 2 more articles in the media than vTv Therapeutics. MarketBeat recorded 6 mentions for Canopy Growth and 4 mentions for vTv Therapeutics. vTv Therapeutics' average media sentiment score of 1.50 beat Canopy Growth's score of 0.86 indicating that vTv Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
vTv Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Canopy Growth	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Positive

vTv Therapeutics presently has a consensus price target of $55.83, indicating a potential upside of 74.64%. Given vTv Therapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe vTv Therapeutics is more favorable than Canopy Growth.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
vTv Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78
Canopy Growth	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20

vTv Therapeutics has a net margin of 0.00% compared to Canopy Growth's net margin of -65.33%. vTv Therapeutics' return on equity of -6.27% beat Canopy Growth's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
vTv Therapeutics	N/A	-6.27%	-5.06%
Canopy Growth	-65.33%	-21.91%	-14.34%

vTv Therapeutics has higher earnings, but lower revenue than Canopy Growth. vTv Therapeutics is trading at a lower price-to-earnings ratio than Canopy Growth, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
vTv Therapeutics	$1.02M	123.49	-$26.97M	-$1.06	N/A
Canopy Growth	$293.63M	1.42	-$190.29M	-$0.45	N/A

Summary

vTv Therapeutics beats Canopy Growth on 12 of the 17 factors compared between the two stocks.

How does vTv Therapeutics compare to Adherex Technologies?

Adherex Technologies (NASDAQ:FENC) and vTv Therapeutics (NASDAQ:VTVT) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their institutional ownership, risk, media sentiment, valuation, earnings, analyst recommendations, profitability and dividends.

Adherex Technologies has a beta of 1.1, suggesting that its share price is 10% more volatile than the broader market. Comparatively, vTv Therapeutics has a beta of 0.29, suggesting that its share price is 71% less volatile than the broader market.

Adherex Technologies has higher revenue and earnings than vTv Therapeutics. Adherex Technologies is trading at a lower price-to-earnings ratio than vTv Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Adherex Technologies	$44.64M	8.61	-$9.74M	-$0.13	N/A
vTv Therapeutics	$1.02M	123.49	-$26.97M	-$1.06	N/A

Adherex Technologies currently has a consensus price target of $17.00, suggesting a potential upside of 55.11%. vTv Therapeutics has a consensus price target of $55.83, suggesting a potential upside of 74.64%. Given vTv Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe vTv Therapeutics is more favorable than Adherex Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Adherex Technologies	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
vTv Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78

In the previous week, Adherex Technologies had 8 more articles in the media than vTv Therapeutics. MarketBeat recorded 12 mentions for Adherex Technologies and 4 mentions for vTv Therapeutics. vTv Therapeutics' average media sentiment score of 1.50 beat Adherex Technologies' score of -0.22 indicating that vTv Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Adherex Technologies	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
vTv Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

55.5% of Adherex Technologies shares are owned by institutional investors. Comparatively, 17.5% of vTv Therapeutics shares are owned by institutional investors. 10.7% of Adherex Technologies shares are owned by insiders. Comparatively, 6.0% of vTv Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

vTv Therapeutics has a net margin of 0.00% compared to Adherex Technologies' net margin of -6.09%. Adherex Technologies' return on equity of -5.71% beat vTv Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Adherex Technologies	-6.09%	-5.71%	-2.37%
vTv Therapeutics	N/A	-6.27%	-5.06%

Summary

Adherex Technologies beats vTv Therapeutics on 9 of the 17 factors compared between the two stocks.

Get vTv Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VTVT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

VTVT vs. The Competition

Export

Metric	vTv Therapeutics	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$125.49M	$12.43B	$7.13B	$12.72B
Dividend Yield	N/A	2.62%	2.56%	11.15%
P/E Ratio	-30.16	799.75	275.24	25.29
Price / Sales	123.49	763.36	656.02	98.94
Price / Cash	N/A	89.25	77.04	51.44
Price / Book	1.95	10.39	10.33	6.20
Net Income	-$26.97M	$2.85B	$3.50B	$358.50M
7 Day Performance	-4.14%	-3.61%	-3.32%	-2.35%
1 Month Performance	0.60%	0.86%	-0.41%	-2.77%
1 Year Performance	61.14%	3.47%	19.21%	7.63%

vTv Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
VTVT vTv Therapeutics	3.6154 of 5 stars	$31.97 +0.3%	$55.83 +74.6%	+56.1%	$125.49M	$1.02M	N/A	9	Positive News
RLMD Relmada Therapeutics	2.9211 of 5 stars	$4.25 -4.1%	$12.00 +182.4%	+197.4%	$472.55M	N/A	N/A	10	News Coverage Positive News Insider Trade Gap Up
AVIR Atea Pharmaceuticals	2.3534 of 5 stars	$5.68 -2.6%	$7.00 +23.2%	+60.9%	$467.60M	N/A	N/A	70	News Coverage Positive News Analyst Upgrade
BIOA BioAge Labs	2.5769 of 5 stars	$9.40 -2.0%	$36.57 +289.1%	+72.9%	$440.15M	$8.99M	N/A	N/A	Analyst Forecast
CGC Canopy Growth	0.9274 of 5 stars	$0.97 -0.7%	N/A	-33.3%	$437.03M	$293.63M	N/A	1,128

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:VTVT) was last updated on 9/12/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

vTv Therapeutics (VTVT) Competitors

VTVT vs. RLMD, AVIR, BIOA, CGC, and FENC

How does vTv Therapeutics compare to Relmada Therapeutics?

Summary

How does vTv Therapeutics compare to Atea Pharmaceuticals?

Summary

How does vTv Therapeutics compare to BioAge Labs?

Summary

How does vTv Therapeutics compare to Canopy Growth?

Summary

How does vTv Therapeutics compare to Adherex Technologies?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VTVT vs. The Competition

vTv Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

vTv Therapeutics (VTVT) Competitors

VTVT vs. RLMD, AVIR, BIOA, CGC, and FENC

How does vTv Therapeutics compare to Relmada Therapeutics?

Do institutionals and insiders have more ownership in RLMD or VTVT?

Which has stronger earnings and valuation, RLMD or VTVT?

Do analysts rate RLMD or VTVT?

Is RLMD or VTVT more profitable?

Which has more risk and volatility, RLMD or VTVT?

Does the media prefer RLMD or VTVT?

Summary

How does vTv Therapeutics compare to Atea Pharmaceuticals?

Do institutionals & insiders hold more shares of VTVT or AVIR?

Do analysts rate VTVT or AVIR?

Does the media refer more to VTVT or AVIR?

Is VTVT or AVIR more profitable?

Which has more risk & volatility, VTVT or AVIR?

Which has stronger valuation & earnings, VTVT or AVIR?

Summary

How does vTv Therapeutics compare to BioAge Labs?

Do analysts recommend BIOA or VTVT?

Do insiders and institutionals believe in BIOA or VTVT?

Which has more risk and volatility, BIOA or VTVT?

Which has better earnings & valuation, BIOA or VTVT?

Does the media prefer BIOA or VTVT?

Is BIOA or VTVT more profitable?

Summary

How does vTv Therapeutics compare to Canopy Growth?

Which has more risk & volatility, VTVT or CGC?

Do insiders & institutionals believe in VTVT or CGC?

Does the media refer more to VTVT or CGC?

Do analysts recommend VTVT or CGC?

Is VTVT or CGC more profitable?

Which has better earnings & valuation, VTVT or CGC?

Summary

How does vTv Therapeutics compare to Adherex Technologies?

Which has more risk & volatility, FENC or VTVT?

Which has preferable valuation and earnings, FENC or VTVT?

Do analysts rate FENC or VTVT?

Does the media prefer FENC or VTVT?

Do insiders and institutionals hold more shares of FENC or VTVT?

Is FENC or VTVT more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VTVT vs. The Competition

vTv Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools